EW News and Press, Edwards Lifesciences Corporation From 03/20/24

2024-03-20 07:44:44 ET More on the markets SPY: Assessing Economic Risks And Market Trends (Technical Analysis, Rating Downgrade) SPY Is Expensive, But There Are Hiding Places S&P 500: Time To Hedge, Here's How Bull vs. Bear: What’s next for the S&...

Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A...

2024-03-07 14:12:00 ET More on Edwards Lifesciences Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained) Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Call Transcript Edward Lifesciences: Still Not A Buy But Getting Closer ...

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of t...

Vancouver, British Columbia--(Newsfile Corp. - February 23, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to comment on its financial results for the nine months ended December 31, 2023. During the nine months ended December 31, 2023, the Company genera...

2024-02-14 13:27:48 ET Summary Edwards Lifesciences achieved 13% organic revenue growth and received FDA approval for their EVOQUE tricuspid valve replacement system. The company plans to spin off its low-growth Critical Care business to focus on the rapidly expanding structural h...

2024-02-12 16:09:46 ET Despite the challenges posed by COVID-19 and macroeconomic headwinds, the company achieved positive revenue growth in 2023. Net sales increased by $622.4 million compared to the previous year, driven by sales growth of their TAVR products. Although the gross profit incr...

2024-02-06 21:05:23 ET Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Conference Call February 06, 2024, 05:00 PM ET Company Participants Mark Wilterding - Investor Relations and Treasurer Bernard Zovighian - Chief Executive Officer Scott Ullem - Chief Fi...

2024-02-06 16:20:14 ET More on Edwards Lifesciences Edward Lifesciences: Still Not A Buy But Getting Closer Edwards Lifesciences: Undervalued With A Substantial Upside Potential Edwards Lifesciences Q4 2023 Earnings Preview Edwards stock jumps 8% on FDA appro...

Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...